Insomnia News and Research

Latest Insomnia News and Research

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences International, Inc. received approval of the New Drug Application (NDA) for BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA).

9 Jun 2014

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Merck, known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the company's global Phase 3 clinical trial, ONCEMRK.

6 Jun 2014

Usage of marijuana impairs quality of sleep

A new study suggests that marijuana use is associated with impaired sleep quality.

3 Jun 2014

Study suggests that circadian factors may contribute to suicidality

A new study provides novel evidence suggesting that suicides are far more likely to occur between midnight and 4 a.m. than during the daytime or evening.

3 Jun 2014

Orexo US partners with inVentiv Health to market Zubsolv sublingual tablets in the US

Orexo AB announces a new partnership between Orexo US, Inc. and inVentiv Health for the commercialization of Zubsolv in the US.

20 May 2014

Study: Sleep apnea common among survivors of acute respiratory failure

Clinically important sleep apnea is common among survivors of acute respiratory failure, according to a new study presented at the 2014 American Thoracic Society International Conference.

19 May 2014

Viewpoints: Battle for Medicaid; GOP's report on enrollment off base; need for kidney donations

The final battle of the war over the Affordable Care Act is being waged today over expanding Medicaid. ... The refusal of more than half the states to cover so many of their neediest citizens - the number who have fallen into the "coverage gap" is estimated at 5 million - amazes and frustrates health experts.

6 May 2014

Virtual patient, medical record and questions appear effective in recognizing suicide risk

A virtual patient, the electronic medical record, and questions about how well patients sleep appear effective new tools in recognizing suicide risk, researchers say.

6 May 2014

Free educational event for patients with Graves' disease and thyroid eye disease

The Massachusetts Eye and Ear and the Graves' Disease & Thyroid Foundation will host a free educational event for patients living with Graves' disease and thyroid eye disease on Saturday, May 10 from 8:30 a.m. to noon at Mass. Eye and Ear's Meltzer Auditorium, 3rd floor, 243 Charles Street, Boston, Mass., 02114.

30 Apr 2014

Johns Hopkins research may help manage the disruptive effects experienced by shift workers

Johns Hopkins researchers report that they have identified a protein essential to the formation of the tiny brain region in mice that coordinates sleep-wake cycles and other so-called circadian rhythms.

26 Apr 2014

Pernix completes sale of Pernix Manufacturing to Woodfield Pharmaceutical

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, today announced that it has closed on the sale of its Houston, TX-based manufacturing operations, Pernix Manufacturing, LLC ("PML") to Woodfield Pharmaceutical LLC.

25 Apr 2014

Sleeping more than 8 hours favours development of cognitive impairment in people over 65

Sleeping more than 8 hours and less than 6 and the lack of cognitive stimulation such as reading favours the development of cognitive impairment in people over 65. This is the main conclusion of a study carried out by researchers from the Department of Pharmacy at the University CEU Cardenal Herrera and pharmacists in the Valencian Region (Spain).

23 Apr 2014

Benzodiazepines may contribute to respiratory problems in people with COPD

A group of drugs commonly prescribed for insomnia, anxiety and breathing issues "significantly increase the risk" that older people with chronic obstructive pulmonary disease, or COPD, need to visit a doctor or Emergency Department for respiratory reasons, new research has found.

21 Apr 2014

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.

8 Apr 2014

Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Astellas Pharma Inc. and Medivation Inc. today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI® (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

4 Apr 2014

Wen Dan Tang significantly reduces insomnia-related anxiety

Ghrelin, a brain-gut peptide that induces anxiety and other abnormal emotions, contributes to the effects of insomnia on emotional behavior. In contrast, the traditional Chinese Medicine remedy Wen Dan Tang reduces insomnia-related anxiety, which may perhaps correspond to changes in the brain-gut axis.

1 Apr 2014

Insomnia News and Research

Latest Insomnia News and Research

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Usage of marijuana impairs quality of sleep

Study suggests that circadian factors may contribute to suicidality

Orexo US partners with inVentiv Health to market Zubsolv sublingual tablets in the US

Study: Sleep apnea common among survivors of acute respiratory failure

Viewpoints: Battle for Medicaid; GOP's report on enrollment off base; need for kidney donations

Virtual patient, medical record and questions appear effective in recognizing suicide risk

Free educational event for patients with Graves' disease and thyroid eye disease

Johns Hopkins research may help manage the disruptive effects experienced by shift workers

Pernix completes sale of Pernix Manufacturing to Woodfield Pharmaceutical

Sleeping more than 8 hours favours development of cognitive impairment in people over 65

Benzodiazepines may contribute to respiratory problems in people with COPD

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Wen Dan Tang significantly reduces insomnia-related anxiety

Simple tool may aid insomnia diagnoses

Forest Laboratories, Richter report positive results from cariprazine Phase IIb trial for bipolar depression

New research reveals how good sleep can help chronic pain sufferers

Nightmares heighten insomnia impact on depression

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Insomnia News and Research

Latest Insomnia News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in